



## Letter to the Editor

# A genetic variant near *TSLP* is associated with chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease in Japanese populations



Dear Editor,

Chronic rhinosinusitis with nasal polyps (CRSwNP), is a heterogeneous disease associated with asthma, high degrees of disease severity, and a poor quality of life.<sup>1</sup> Some patients with CRSwNP have a specific condition called aspirin-exacerbated respiratory disease (AERD) which is characterized by a triad of symptoms including CRSwNP, asthma, and sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs).<sup>1,2</sup>

Genome-wide association studies (GWASs) have found significant associations between the *thymic stromal lymphopoietin* (*TSLP*) locus and asthma, allergic rhinitis, eosinophilic esophagitis, and nasal polyps (Supplementary Table 1).<sup>3</sup> *TSLP* is produced by barrier epithelial cells and plays a central role in activating type 2-related inflammatory cells including T<sub>H</sub>2 lymphocytes, type 2 innate lymphoid cells, eosinophils, basophils, and mast cells.<sup>2,4</sup> A recent study examined the presence of *TSLP*, IL-25 and IL-33 in nasal polyps from patients with CRSwNP and AERD and found significant elevations of *TSLP* mRNA in nasal polyps from CRSwNP and AERD compared to controls.<sup>5</sup> Another study has shown that *TSLP* activates eosinophils and induces the expression of mast cell-derived PGD<sub>2</sub> via mast cells, which plays a crucial role in the pathophysiology of AERD.<sup>2</sup> To improve our understanding of the molecular mechanisms of the CRSwNP and AERD, we performed an association study of CRSwNP and AERD with genetic variants in the *TSLP* locus (Supplementary Table 2).

We recruited a total of 499 patients with CRSwNP who received their diagnoses by otolaryngologists. We also recruited a total of 194 patients with AERD. We searched the NHGRI-EBI catalog of published genome-wide association studies for *TSLP* (<https://www.ebi.ac.uk/gwas/search>). A total of 11 GWASs have reported an association of the *TSLP* locus with allergy-related phenotypes (Supplementary Table 1). We assessed the eight variants that showed the most significant associations at the *TSLP* locus among GWASs (Supplementary Table 3, Supplementary Fig. 1). The study populations and methods are described in detail in the Supplementary Methods.

We first conducted an association study of CRSwNP in the 303 cases and 904 controls for the primary set. We found significant associations between CRSwNP and rs1837253, rs3806932 and rs3806933, with the most significant association being observed

at rs1837253 ( $P = 1.27 \times 10^{-6}$ ; odds ratio, 1.60; 95% CI, 1.32–1.94), which is located 5.7 kb upstream of the *TSLP* gene (Supplementary Table 3). We next conducted conditional logistic regression analysis for rs1837253, but no additional independent association signals were observed (Supplementary Table 3). We then performed a validation study for rs1837253 using an independent set of 196 CRSwNP cases and 1004 controls and observed a significant association with CRSwNP after combining the results using fixed-effects meta-analysis ( $P_{\text{combined}} = 1.01 \times 10^{-10}$ ; odds ratio, 1.61; 95% CI, 1.40–1.86) (Table 1). Interestingly, a recent GWAS on nasal polyps in individuals of European descent reported a significant association at rs1837253 ( $P = 3.7 \times 10^{-29}$ ; odds ratio, 1.35; 95% CI, 1.28–1.43), and the effect of allele was in the same direction.<sup>3</sup>

We stratified 499 patients with CRSwNP by comorbidity of AERD, and a total of 68 subjects among the 499 patients had AERD (Supplementary Table 2). We conducted an association study of AERD and rs1837253 in the 68 cases and 900 controls for the primary set and observed a significant association ( $P = 1.16 \times 10^{-3}$ ; odds ratio, 1.78; 95% CI, 1.26–2.52). We further performed a replication study using an independent set of 126 AERD cases and 1004 controls for the validation set, and observed a significant association ( $P_{\text{combined}} = 4.84 \times 10^{-6}$ ; odds ratio, 1.64; 95% CI, 1.33–2.04) (Table 1, Supplementary Table 2).

We next assessed whether the number of eosinophils in mucosal tissues of patients with CRSwNP correlated with the rs1837253 genotype. We examined correlations between genotypes and the eosinophil numbers in nasal polyps by linear regression analysis. Interestingly, a significant positive correlation between the risk allele and the number of eosinophils was observed ( $P = .017$ ) (Fig. 1). A recent study has shown the influence of the rs1837253 genotype on *TSLP* secretion in response to double-stranded RNA in human nasal epithelium.<sup>6</sup> The study showed decreased *TSLP* secretion in subjects with the TT and CT genotypes, and suggested that rs1837253 might be directly involved in the regulation of *TSLP* secretion.<sup>6</sup>

To investigate the impact of the rs1837253 variant on the binding affinities of transcription factors, we next conducted electrophoretic mobility shift assay. Functional annotations using the HaploReg v4.1 tool indicated that rs1837253 mapped to enhancer histone marks H3K4me1 and H3K27ac in a fetal lung fibroblast cell line. *TSLP* mRNA and protein are expressed

Peer review under responsibility of Japanese Society of Allergy.

<https://doi.org/10.1016/j.alit.2019.06.007>


1323-8930/Copyright © 2019, Japanese Society of Allergy. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1**

Association results of rs1837253 in CRSwNP and AERD.

Stage	Subject	Genotype			Total	RAF	P value <sup>†</sup>	OR (95% CI) <sup>†</sup>	P het <sup>‡</sup>
		TT	TC	CC					
<b>CRSwNP</b>									
Primary	Case	93	146	64	303	0.45	$1.27 \times 10^{-6}$	1.60 (1.32–1.94)	
	Control	396	395	109	900	0.34			
Validation	Case	61	92	43	196	0.45	$1.78 \times 10^{-5}$	1.63 (1.30–2.04)	
	Control	449	431	122	1002	0.34			
Combined							$1.01 \times 10^{-10}$	1.61 (1.40–1.86)	0.900
<b>AERD</b>									
Primary	Case <sup>§</sup>	25	20	23	68	0.49	$1.16 \times 10^{-3}$	1.78 (1.26–2.52)	
	Control	396	395	109	900	0.34			
Validation	Case	35	67	23	125	0.45	$1.08 \times 10^{-3}$	1.57 (1.20–2.05)	
	Control	449	431	122	1002	0.34			
Combined							$4.86 \times 10^{-6}$	1.64 (1.33–2.04)	0.575

RAF, risk allele frequency; OR, odds ratio; CI, confidence interval.

<sup>†</sup> P values and ORs of the logistic regression test with adjustment for sex and age as covariates. Results of combined analyses were calculated using fixed-effects meta-analysis.<sup>‡</sup> P values of Cochran's heterogeneity statistics.<sup>§</sup> Among a total of 499 patients with CRSwNP (303 cases in primary set and 196 cases in validation set), a total of 68 subjects had AERD.**Fig. 1.** Relationship between rs1837253 genotype and the number of eosinophils in CRSwNP ( $n = 240$ ). The P value was calculated by linear regression analysis ( $P = .017$ ). Log-transformed individual eosinophil numbers are used in the figure. Zero was replaced by 0.1 before log transformation.

in epithelial cells, fibroblasts, and endothelial cells in nasal polyps.<sup>7</sup> We investigated the influence of the rs1837253 variant on the binding affinities of transcription factors using nuclear extracts from nasal fibroblasts. The signal intensity of the DNA–protein complex derived from the susceptible C allele of rs1837253 was higher than that from the T allele in the presence of the nuclear extract (Supplementary Fig. 2). We next examined putative transcription factor binding sites in the DNA sequences, and rs1837253 was found to potentially alter the affinities of two transcription factors, upstream stimulatory factor (USF) 1 and USF2. The findings of a super-shift binding assay using anti-USF1 and -USF2 antibodies suggested that rs1837253 altered nuclear-factor recruitment to the site (Supplementary Fig. 2). Interestingly, USF1-regulated genes are associated with immune response following viral and bacterial infections,<sup>8</sup> and USF1 and USF2 are indispensable for the transcription of ROR $\gamma$ T, which regulates the development of Th17 cells and the expression of IL-17.<sup>9</sup>

In conclusion, we identified significant associations between rs1837253 near *TSLP* and susceptibility to CRSwNP and AERD, and also found a positive correlation between the risk allele and the

number of eosinophils in mucosal tissues of patients with CRSwNP. Our functional study suggests an allele-specific influence of rs1837253 on affinity for USF1 and USF2 in nasal fibroblasts. Since type 2 immune responses driven by TSLP is known to contribute to both of the pathophysiology of AERD and CRSwNP,<sup>1,2</sup> the shared genetic risk might influence dysregulation of the innate system. Further studies are warranted to investigate the roles of the variants near *TSLP* in the pathogenesis of those chronic inflammatory airway diseases.

## Acknowledgments

The authors are grateful to all participants in the study. We thank K. Barrymore for proofreading this document. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and Japan Agency for Medical Research and Development (AMED), and by Health and Labor Science Research Grants for Research on Allergic Disease and Immunology from the Ministry of Health, Labor and Welfare of Japan.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.alit.2019.06.007>.

## Conflict of interest

The authors have no conflict of interest to declare.

Tsuguhisa Nakayama <sup>a,b</sup>, Tomomitsu Hirota <sup>b,c</sup>, Daiya Asaka <sup>a</sup>, Masafumi Sakashita <sup>d</sup>, Takahiro Ninomiya <sup>d</sup>, Taiyo Morikawa <sup>d</sup>, Mitsuhiro Okano <sup>e</sup>, Shinichi Haruna <sup>f</sup>, Naohiro Yoshida <sup>g</sup>, Sachio Takeno <sup>h</sup>, Yasuhiro Tanaka <sup>i</sup>, Mamoru Yoshikawa <sup>j</sup>, Junichi Ishitoya <sup>k</sup>, Nobuyuki Hizawa <sup>l</sup>, Sumito Isogai <sup>m</sup>, Chihiro Mitsui <sup>n</sup>, Masami Taniguchi <sup>n</sup>, Hiromi Kojima <sup>a</sup>, Shigeharu Fujieda <sup>d</sup>, Mayumi Tamari <sup>b,c,\*</sup>

<sup>a</sup> Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan

<sup>b</sup> Laboratory for Respiratory and Allergic Diseases, Center for Integrative Medical Sciences, Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan

<sup>c</sup> Division of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan

<sup>d</sup> Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Fukui, Fukui, Japan

<sup>e</sup> Department of Otolaryngology Head & Neck Surgery, Okayama University Graduate School of Medicine, Okayama, Japan

<sup>f</sup> Department of Otorhinolaryngology Head & Neck Surgery, Dokkyo Medical University, Tochigi, Japan

<sup>g</sup> Department of Otolaryngology, Jichi Medical University Saitama Medical Center, Saitama, Japan

<sup>h</sup> Department of Otorhinolaryngology-Head & Neck Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

<sup>i</sup> Department of Otolaryngology, Dokkyo Medical University, Koshigaya Hospital, Saitama, Japan

<sup>j</sup> Department of Otorhinolaryngology, Toho University Ohashi Medical Center, Tokyo, Japan

<sup>k</sup> Department of Otorhinolaryngology, Yokohama City University Medical Center, Kanagawa, Japan

<sup>l</sup> Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan

<sup>m</sup> Department of Respiratory Medicine, Fujita Health University, Aichi, Japan

<sup>n</sup> Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan

\* Corresponding author. Division of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan.

E-mail address: [mayumitamari@jikei.ac.jp](mailto:mayumitamari@jikei.ac.jp) (M. Tamari).

## References

- Bachert C, Pawankar R, Zhang L, Bunnag C, Fokkens WJ, Hamilos DL, et al. ICON: chronic rhinosinusitis. *World Allergy Organ J* 2014;**7**:25.
- Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D<sub>2</sub> generation in patients with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol* 2016;**137**:1566–76.
- Kristjansson RP, Benonisdottir S, Davidsson OB, Oddsson A, Tragante V, Sigurdsson JK, et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. *Nat Genet* 2019;**51**:267–76.
- Ziegler SF. Thymic stromal lymphopoietin and allergic disease. *J Allergy Clin Immunol* 2012;**130**:845–52.
- Ogasawara N, Klingler AI, Tan BK, Poposki JA, Hulse KE, Stevens WW, et al. Epithelial activators of type 2 inflammation: elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. *Allergy* 2018;**73**:2251–4.
- Hui CC, Yu A, Heroux D, Akhbar L, Sandford AJ, Neighbour H, et al. Thymic stromal lymphopoietin (TSLP) secretion from human nasal epithelium is a function of TSLP genotype. *Mucosal Immunol* 2015;**8**:993–9.
- Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. *J Allergy Clin Immunol* 2013;**132**:593–600.
- Corre S, Galibert MD. Upstream stimulating factors: highly versatile stress-responsive transcription factors. *Pigment Cell Res* 2005;**18**:337–48.
- Ratajewski M, Walczak-Drzewiecka A, Salkowska A, Dastych J. Upstream stimulating factors regulate the expression of ROR $\gamma$ T in human lymphocytes. *J Immunol* 2012;**189**:3034–42.

Received 3 April 2019

Received in revised form 30 May 2019

Accepted 19 June 2019

Available online 17 July 2019